Acceptance of an Mpox Vaccine in the Democratic Republic of the Congo

Skylar Petrichko[1]*, Jason Kindrachuk[2]*, Dalau Nkamba[3], Megan Halbrook[1], Sydney Merritt[1],

Handdy Kalengi[3], Leonard Kamba[3], Michael Beya[3], Nicole A. Hoff[1], Christophe Luhata[4], Didine

K. Kaba[3#], Anne W. Rimoin[1#]

* Denotes co-first authors. These authors contributed equally to this article.

# Denotes co-last authors

Author Affiliation:

1.   Department of Epidemiology, Jonathan and Karin Fielding School of Public Health,
University of California, Los Angeles, CA, USA
2.   Department of Medical Microbiology & Infectious Diseases, Max Rady College of
Medicine, University of Manitoba, Winnipeg, MB, Canada
3.   Kinshasa School of Public Health, University of Kinshasa, Democratic Republic of
the Congo
4.   Expanded Programme for Immunization, Ministry of Health, Democratic Republic of
the Congo

Corresponding Author:

Anne W. Rimoin, PhD, MPH
Professor, Department of Epidemiology, Gordon-Levin Endowed Chair in Infectious Diseases
and Public Health
Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles
650 Charles E. Young Dr, CHS 41-275, Los Angeles, CA, 90095
+1 (310) 825-2096, arimoin@ucla.edu

KEYWORDS mpox; vaccination; Democratic Republic of the Congo; MPXV

WORD COUNTS Abstract - 48; Text - 1289

ABSTRACT

We report general acceptance of an mpox vaccine (61.0%) in the Democratic Republic of the Congo (n = 5226) with higher acceptance among healthcare workers and respondents in historic mpox-endemic regions. These data highlight the need for increased community engagement and sensitization before widespread deployment of mpox vaccines.

INTRODUCTION

Mpox is a zoonotic infectious disease endemic to the Democratic Republic of the Congo (DRC) (1-3). In 2022, rapid spread of MPXV Clade IIb worldwide resulted in over 91,000 confirmed infections and the declaration of a public health emergency of international concern (PHEIC) (4). In the DRC incident cases have quadrupled between 2021 and 2023: over 28,000 suspected cases were reported from January 2023 to July 2024, and new introductions recorded in neighboring Burundi, Rwanda, Kenya, and Uganda (5). In August 2024 a travel-associated Clade Ib case was reported for the first time in Sweden (6). In response to the recent expanding burden of mpox, Africa CDC and the WHO declared a Public Health Emergency of Continental Security and second PHEIC, respectively.

Despite the deployment of a modified vaccinia Ankara-Bavarian Nordic vaccine to many high and middle-income countries, there currently is no mpox vaccine access for the general population in Africa. One vaccination model suggests that vaccination of 80% of children under 15 years old in DRC would result in robust reductions on morbidity, mortality, and mpox circulation (7).

METHODS

The data for this cross-sectional analysis was drawn from a larger longitudinal phone survey which began in 2022 and included participants, targeting primarily HCWs, from all 26 provinces in the DRC. Participants were selected from historical phone survey records of over 10,000 persons. From these records, 5,226 adult participants were contacted between December 2023 to February 2024 by study staff to complete to this vaccine survey. Surveys were administered via phone by trained interviewers in Swahili, French, Lingala, Kikongo, and/or Tshiluba. Survey questions included behavioral and social drivers of vaccination and attitudes towards the introduction of new vaccines, including mpox. Mpox vaccine acceptance was measured by asking participants about their interest in the inclusion of a an mpox vaccine in the national vaccination schedule and participants were given several response choices—yes, for either adults, children or both; no; and I do not know this disease (Supplementary Material 1). All 'yes' responses were collapsed for analysis. Attitudes, vaccine acceptance by province, and sociodemographic characteristics were assessed via Likert scale questions and presented as a 5- or 3-level variable and chi-square test ($\alpha=0.05$).

Ethics approval was provided by the Kinshasa School of Public Health (ESP/CE/188/2023) and the University of California, Los Angeles, as a public health response activity designation.

RESULTS

Respondents were predominantly male (79.2%), with the highest percentage from Kwilu
province (12.6%). There was roughly equivalent representation of those from urban or rural
settings. Most respondents reported some college/university education (41.2%) and identified as
healthcare workers (55.5%) **(Table 1)**.

Participants generally disagreed with the statement that new vaccines carry more risks than older
vaccines. However, in four provinces—Sud Kivu, Nord Ubangi, Nord Kivu, and Lualaba—more
than 50% of respondents agreed with or felt that greater risks exist. Respondents generally
agreed with the statement that information received about vaccines from the vaccination program
was reliable and trustworthy. In Sankuru province, 29.5% of respondents felt neutral about the
reliability of vaccine program information; Haut Katanga and Lomami had the highest
prevalence of vaccine information distrust, with 7.6% and 6.8% disagreeing with the statement.
(Figure 1).

Nationally, there was general acceptance of an mpox vaccination by all respondents (61.0%, 95%
CI:59.6-62.4); 21.7% had no interest, and 17.3% reported no knowledge of mpox. At the
provincial level, more than 80% of respondents from Kwango, Tshuapa, Nord Ubangi,
Tanganyika, and Maniema were accepting of a vaccine, while respondents from Sankuru had the
lowest acceptance (19.9%, 95% CI:14.3-26.6). Sankuru also had the highest percentage of
participants that reported no mpox knowledge (57.4%, 95% CI:49.7-64.8). In general, rates of
mpox vaccine acceptance and mpox disease knowledge were not influenced by the history of
mpox cases within the province **(Figure 2)**.

Mpox vaccine acceptance varied significantly by province (p <0.0001). When stratified by
educational attainment, those with a high school diploma had significantly lower acceptance of
the mpox vaccine (49.8% 95%CI: 47.3-52.3) compared with others. Of all occupations reported,
healthcare workers had the highest acceptance rates (69.4%, 95% CI: 67.6-71.1). Respondents
from rural locations indicated greater acceptance of mpox vaccine deployment than their urban
counterparts (64.4% vs 57.7%, p<0.0001). Among respondents who reported receiving a
COVID-19 vaccine (n=4396), 63.2% indicated mpox vaccine acceptance. Additionally, persons
who reported experiencing no chronic conditions reported higher rates of mpox vaccine
acceptance (62.2% vs 51.0%) **(Figure 3)**.

CONCLUSION

Given the ongoing escalation of the concurrent DRC Clade Ia and Clade Ib outbreaks and recent
identification of cases in adjacent countries in Central Africa, there is increasing need for the
rapid introduction of an mpox vaccine. However, to date, there is a paucity of information
regarding mpox vaccine acceptance and mpox knowledge across DRC. We observed greater
interest in mpox vaccine deployment among respondents from rural locations compared with
urban populations. This is perhaps explained by the historic burden of mpox in DRC as mpox

cases were primarily identified among children in rural regions. Currently, reported mpox cases
are rising in urban centers, further challenging response and vaccine planning efforts.

Assessing mpox vaccine trust and acceptance across provinces that have and have not
experienced mpox cases, and across demographic variables did not yield clear or neatly
described trends. Instead, we observed several instances of outliers that may reflect the
uniqueness and diversity of the DRC. For example, differing vaccine acceptance rates between
those with and without chronic conditions may indicate underlying health anxieties among those
with persistent health problems; further investigation is needed to better understand this
relationship. Additionally, Sankuru province was consistently a vaccine hesitant outlier. Sankuru
had the lowest proportion of respondents who trust information received from national vaccine
programs and the lowest mpox vaccine acceptance, primarily because 57.4% of respondents
stated no knowledge of mpox. In DRC, the majority of mpox endemic provinces consist of
rainforest or forest-savannah mosaic geographies; the southeast provinces are primarily savanna
and grassland and with no history of reported mpox cases. However, in June 2024 Lualaba
reported their first mpox case. Interestingly, this province had the highest proportion of
respondents believing that new vaccines have greater risks than older vaccines, though overall
trust in national vaccine programs was high.

While these results report an overall trend of vaccine trust and acceptance nation-wide, they also
indicate the need for a multifaceted approach to vaccine education and rollout. Strategies should
be tailored to historically endemic regions and/or areas with lower vaccine acceptance, such as
Sankuru or Kasai Central, and consider how personal experiences and cultural considerations
intersect with mpox outbreaks. Of note, Haut Lomami province has been the setting of long-
standing routine immunization revitalization efforts (8, 9), and 100% of respondents from this
province reported that they feel information from the national vaccine program is reliable. This
highly positive response is perhaps reflective of the many years of vaccine campaigns and
education efforts in this region.

This survey was limited to those with access to phones; individuals with a lower socioeconomic
status may have been inadvertently excluded from this study, including those in largely rural
regions. This study included respondents from all provinces in DRC, with an emphasis on
recruiting HCW. Past studies in the DRC have demonstrated 54% acceptance towards outbreak-
related vaccines, with HCW continually expressing the highest acceptance among all
respondents (10). As this study sought to enroll HCWs, and community and religious leaders, we
observed an over-representation of men as they primarily hold these leadership roles in the DRC.
As HCWs and religious leaders serve as health recommenders for their communities, there is a
critical need to identify and address vaccine acceptance among these groups. These data provide
insight regarding future deployments in adjacent regions as well as vaccine acceptance and
deployment strategies within DRC, or regionally, for other emerging infectious diseases.

ACKNOWLEDGEMENTS

All cartographic figures were generated using qGIS (Maidenhead, 3.36.3). We thank Brooke
Aksnes and Emma Wray Aberle-Grasse for their continued support of this ongoing research
endeavor.

FUNDING

This work was supported by funding from the Centers for Disease Control and Prevention (CDC)
through the Task Force for Global Health (TFGH) under Cooperative Agreement # 6
NU2RGH001916-02-06. The content of the information does not necessarily reflect the position
or the policy of TFGH, and no official endorsement should be inferred.

REFERENCES

1.   AI B. Human monkeypox, 1970-79. Bull World Health Organ. 1980;58:165182.
2.   Foster SO, Brink EW, Hutchins DL, Pifer JM, Lourie B, Moser CR, et al. Human
monkeypox. Bull World Health Organ. 1972;46(5):569-76.
3.   Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in
Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ.
1972;46(5):593-7.
4.   (WHO) WHO. Mpox (monkeypox) Outbreak. Emergencies 2024 [cited 2024; Available
from: https://www.who.int/europe/emergencies/situations/monkeypox
5.   (SGI-MPOX) SdGdLEM. Epidemie de Mpox en Republique Democratique du Congo;
Rapport de Situation No. 027. Kinshasa, DRC: Institut National de Sante Publique; 2024.
6.   Mpox due to monkeypox virus clade I. Epidemiological Update: European Center for
Disease Prevention and Control (ECDC); 2024.
7.   Savinkina A, Kindrachuk J, Bogoch I, Rimoin AW, Hoff NA, Shaw SY, et al. Modeling
Vaccination Approaches for Mpox Containment and Mitigation in the Democratic Republic of
the Congo. Available at SSRN 4759169. 2024.
8.   Lame P, Milabyo A, Tangney S, Mbaka GO, Luhata C, Gargasson JL, et al. A Successful
National and Multipartner Approach to Increase Immunization Coverage: The Democratic
Republic of Congo Mashako Plan 2018-2020. Glob Health Sci Pract. 2023 Apr 28;11(2).
9.   Banza Mpiongo P, Kibanza J, Kambol Yav F, Nyombo D, Mwepu L, Basame D, et al.
Strengthening immunization programs through innovative sub-national public-private
partnerships in selected provinces in the Democratic Republic of the Congo. Vaccine. 2023
2023/12/12/;41(51):7598-607.
10.   Peckeu-Abboud L, Mangoni P, Chammam K, Kwete P, Mutombo Lupola P, Vanlerberghe
V, et al. Drivers of routine and outbreak vaccination uptake in the western Democratic Republic
of Congo: an exploratory study in ten health zones. Vaccines. 2022;10(7):1066.

FIGURES AND TABLES

Table 1. Demographic Characteristics of National Phone Survey Respondents (n = 5226)

Sample characteristic[1]	Frequency n = 5226	
Demographics		
Age (median [IQR])	42	16.0
Gender		
Male	4138	(79.2%)
Female	1088	(20.8%)
Education Level		
Less than high school	359	(6.9%)
Graduated high school	1589	(30.4%)
Some college	2158	(41.3%)
Bachelor or advanced degree	1120	(21.4%)
Province		
Maindombe	134	(2.6%)
Kwango	183	(3.5%)
Kwilu	657	(12.6%)
Kongo Central	312	(6.0%)
Equateur	162	(3.1%)
Mongala	238	(4.6%)
Tshuapa	63	(1.2%)
Nord Ubangi	113	(2.2%)
Sud Ubangi	91	(1.7%)
Kasai Oriental	597	(11.4%)
Sankuru	176	(3.4%)
Lomami	192	(3.7%)
Kasai	118	(2.3%)
Kasai Central	87	(1.7%)
Haut Katanga	331	(6.3%)

Tanganyika	151	(2.9%)
Haut Lomami	50	(1.0%)
Lualaba	168	(3.2%)
Kinshasa	251	(4.8%)
Maniema	98	(1.9%)
North Kivu	140	(2.7%)
Bas Uele	246	(4.7%)
Haut Uele	137	(2.6%)
Ituri	239	(4.6%)
Tshopo	144	(2.8%)
Sud Kivu	148	(2.8%)
Geographic Area		
Urban	2659	(50.9%)
Rural	2567	(49.1%)
Occupation		
Health worker	2899	(55.5%)
Religious leader	89	(1.7%)
Community or essential services leader	768	(14.7%)
Public service sector or educator	670	(12.8%)
Other worker	513	(9.8%)
Not working	287	(5.5%)

Health Information

Health conditions

Chronic lung disease	32	(0.6%)
Diabetes	209	(4.0%)
Cardiovascular disease	254	(4.9%)
Chronic renal disease	12	(0.2%)
Chronic liver disease	9	(0.2%)
Immunocompromised	10	(0.2%)

| No conditions | 4700 | (89.9%) |

Figure 1. General Vaccine Attitudes and Perceptions by Province. (A) Reported responses to the statement "New vaccines carry more risks than older vaccines" (B) Reported responses to the statement "Information I receive about vaccines from the vaccine program is reliable and trustworthy". 3-level responses were collapsed from a 5-point Likert scale.

Figure 2. Map of Overall Mpox Acceptance by Province. (A) Reported acceptance as the collapsed responses of "Yes, for all populations" and "Yes, for children only" and "Yes, for

207   adults only" (B) Reported non-acceptance by the response "No, not interested". (C) Reported
208   lack of knowledge of mpox disease. Percentages are reported by province.

209   (A)

211   (B)

214   (C)

Figure 3. Percent of Mpox Vaccine Acceptance by Province and Demographic Characteristic. Acceptance of an Mpox Vaccine among respondents as stratified by sociodemographic characteristics and known mpox risk factors COVID-19 vaccination was dichotomized by whether the respondent received the COVID-19 vaccine. Health condition was dichotomized based on whether the respondent stated they had a chronic disease or were immunocompromised.

* Chi-sq p-value <.05

Characteristic	n	Percent (95% CI)
*Province		
Bas Uele	125	50.8 (44.6 to 57.0)
Equateur	77	47.8 (40.2 to 55.6)
Haut Katanga	141	66.8 (60.2 to 72.9)
Haut Lomami	20	40.8 (27.9 to 55.1)
Haut Uele	107	78.1 (70.4 to 84.3)
Ituri	134	56.3 (49.9 to 62.5)
Kasai	80	67.8 (58.8 to 75.6)
Kasai Central	32	37.6 (28.0 to 48.4)
Kasai Oriental	416	70.7 (66.9 to 74.3)
Kinshasa	182	72.8 (66.9 to 78.0)
Kongo Central	109	35.3 (30.1 to 40.8)
Kwango	154	84.2 (78.1 to 88.8)
Kwilu	375	58.3 (54.5 to 62.1)
Lomami	102	53.7 (46.5 to 60.7)
Lualaba	92	56.1 (48.4 to 63.5)
Maindombe	82	61.7 (53.1 to 69.5)
Maniema	84	85.7 (77.3 to 91.4)
Mongala	176	73.9 (68.0 to 79.1)
Nord Ubangi	95	84.1 (76.1 to 89.7)
North Kivu	85	60.7 (52.4 to 68.5)
Sankuru	35	19.9 (14.6 to 26.5)
Sud Kivu	82	55.8 (47.6 to 63.6)
Sud Ubangi	45	51.7 (41.2 to 62.1)
Tanganyika	129	85.4 (78.8 to 90.2)
Tshopo	74	51.4 (43.2 to 59.5)
Tshuapa	55	87.3 (76.5 to 93.6)

Characteristic	n	Percent (95% CI)
Gender		
Female	609	58.5 (55.5 to 61.5)
Male	2479	61.7 (60.1 to 63.1)
*Education		
Less than high school	215	60.9 (55.7 to 65.9)
Graduated high school	767	49.8 (47.3 to 52.3)
Some college	1391	66.7 (64.6 to 68.6)
Bachelor or advanced degree	715	66.1 (63.3 to 68.9)
*Occupation		
Health worker	1947	69.4 (67.7 to 71.1)
Community leader	364	48.3 (44.7 to 51.8)
Public Servant or Educator	330	50.8 (46.9 to 54.6)
Religious leader	40	44.9 (34.9 to 55.4)
Other worker	287	58.8 (54.4 to 63.1)
Not working	120	43.6 (37.9 to 49.6)
*Geographic Area		
Rural	1616	64.4 (62.5 to 66.2)
Urban	1472	57.7 (55.8 to 59.6)
*COVID-19 Vaccination		
No	311	46.8 (43.0 to 50.6)
Yes	2777	63.2 (61.7 to 64.6)
*Health Condition		
No	2815	62.2 (60.8 to 63.6)
Yes	273	51.0 (46.8 to 55.3)